Sweden’s research-oriented pharmaceutical firm Medivir AB's Investigational New Drug application for an osteoarthritis treatment has been accepted by, and is currently open with, the U.S. Food and Drug Administration. Read More »
Arcadia Biosciences Inc. and Bioceres S.A. have entered a joint venture titled Verdeca, and announced that the company’s safety evaluation for HB4 soybeans received a full review by the U.S. Food and Drug Administration. Read More »
Soligenix Inc., a late-stage biopharmaceutical company that creates rare-disease targeting products, recently announced that its good manufacturing practices-compliant bulk drug substance, RiVax, has received funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Read More »
Apollo Endosurgery Inc. recently announced an update and clarifications to a letter sent by the U.S. Food and Drug Administration to health care providers about potential risks with liquid-filled intragastric balloons. Read More »
Arcadia Biosciences Inc., an agricultural technology company, recently received FDA approval from the U.S. Food and Drug Administration for the use of its safflower oil in dog diets. Read More »
Regeneron Pharmaceuticals Inc. recently announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), failed to meet its primary endpoint. Read More »
Walgreens recently announced the launch of its Center for Health & Wellbeing Research, a website documenting roughly 50 outcomes from studies the company undertook in the past six years. Read More »
Naloxone, a nasal spray developed as an antidote for opioid overdose, will soon become available to Pennsylvania first responders thanks to support and outreach efforts sponsored by Philadelphia-based managed care provider AmeriHealth Caritas. Read More »
Amneal Pharmaceuticals, based in Bridgewater, New Jersey, has voluntarily recalled 13 lots of Lorazepam Oral Concentrate, USP 2mg/mL, Lorazepam Oral Concentrate, USP 2mg/mL — a product for which the accompanying dropper dispenser may be erroneously labeled. Read More »
Achieving U.S. Food and Drug Administration priority review status for its New Drug Application, Gilead Sciences Inc. recently made strides towards realizing an investigational, fixed-dose product combining several drugs to address HIV-1 infection. Read More »
Regional Cancer Care Associates (RCCA) recently announced its attainment of accreditation by URAC, a leading nonprofit health care benchmark group, as a Specialty Pharmacy in Hackensack, New Jersey. Read More »
Award-winning, Arizona-based Avella Specialty Pharmacy recently launched an e-commerce platform to simplify orders for compounded products — featuring user-friendly, secure web access and streamlining ophthalmologists’ online tasks. Read More »
Health care investment firm Ampersand Capital Partners recently divested its former portfolio firm Roadrunner Pharmacy in a deal transferring Roadrunner to Vets First Choice after five years of supported growth in revenue and EBITDA. Read More »
Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the country, has announced the expansion of a pilot program that limits opioid prescriptions to seven days without prior authorization. Read More »
Innovus Pharmaceuticals has ordered 220,000 units of FlutiCare, putting the drug on pace to meet its planned launch for the fourth quarter of 2017. Read More »
Imprimis Pharmaceuticals Inc. recently released a statement after the MedWatch notification put forth by the U.S. Food and Drug Administration. Read More »
Presenting a quantum leap in telemedicine, Scottsdale, Arizona-based GlobalMed recently released its award-winning branded eNcounter platform, designed to streamline clinical and at-home care and even geared for interoperability with wearable devices, ensuring data based outcomes. Read More »
AbbVie's once-daily treatment for chronic hepatitis C virus (HCV) infection, Mavyret, has been approved by the U.S. Food and Drug Administration. Read More »
La Jolla Pharmaceutical Co. recently initiated an expanded access program (EAP) in the United States for its investigational drug LJPC-501. Read More »
AstraZeneca and Acerta Pharma's treatment for patients with mantle cell lymphoma who have received at least one prior therapy was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration. Read More »
Alerts Sign-up
